Vor Biopharma (VOR) Competitors $31.28 +3.35 (+11.99%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$32.85 +1.58 (+5.04%) As of 09:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VOR vs. AVXL, IMNM, AVBP, PRAX, GOSS, AKBA, VALN, NAGE, SANA, and OCSShould you be buying Vor Biopharma stock or one of its competitors? The main competitors of Vor Biopharma include Anavex Life Sciences (AVXL), Immunome (IMNM), ArriVent BioPharma (AVBP), Praxis Precision Medicines (PRAX), Gossamer Bio (GOSS), Akebia Therapeutics (AKBA), Valneva (VALN), Niagen Bioscience (NAGE), Sana Biotechnology (SANA), and Oculis (OCS). These companies are all part of the "pharmaceutical products" industry. Vor Biopharma vs. Its Competitors Anavex Life Sciences Immunome ArriVent BioPharma Praxis Precision Medicines Gossamer Bio Akebia Therapeutics Valneva Niagen Bioscience Sana Biotechnology Oculis Anavex Life Sciences (NASDAQ:AVXL) and Vor Biopharma (NYSE:VOR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation. Is AVXL or VOR more profitable? Vor Biopharma's return on equity of 0.00% beat Anavex Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Anavex Life SciencesN/A -45.67% -40.21% Vor Biopharma N/A N/A N/A Which has more volatility and risk, AVXL or VOR? Anavex Life Sciences has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Vor Biopharma has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500. Do institutionals & insiders believe in AVXL or VOR? 31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by insiders. Comparatively, 0.5% of Vor Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts prefer AVXL or VOR? Anavex Life Sciences currently has a consensus price target of $44.00, indicating a potential upside of 417.04%. Vor Biopharma has a consensus price target of $113.83, indicating a potential upside of 263.92%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Anavex Life Sciences is more favorable than Vor Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anavex Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Vor Biopharma 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.56 Which has better earnings & valuation, AVXL or VOR? Anavex Life Sciences is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnavex Life SciencesN/AN/A-$43M-$0.57-14.93Vor BiopharmaN/AN/AN/A-$273.20-0.11 Does the media favor AVXL or VOR? In the previous week, Vor Biopharma had 17 more articles in the media than Anavex Life Sciences. MarketBeat recorded 18 mentions for Vor Biopharma and 1 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 1.47 beat Vor Biopharma's score of 0.33 indicating that Anavex Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vor Biopharma 3 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAnavex Life Sciences and Vor Biopharma tied by winning 6 of the 12 factors compared between the two stocks. Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VOR vs. The Competition Export to ExcelMetricVor BiopharmaBiological Products, Except Diagnostic Substances IndustryMedical SectorNYSE ExchangeMarket Cap$198.13M$241.80M$5.76B$21.71BDividend YieldN/AN/A5.53%3.52%P/E Ratio-18.96N/A76.2529.84Price / SalesN/A305.26470.4960.74Price / CashN/AN/A37.4624.72Price / BookN/A2.8913.354.59Net IncomeN/A-$111.70M$3.29B$1.00B7 Day Performance2.89%6.24%1.83%0.64%1 Month Performance-27.93%-35.53%3.98%2.77%1 Year Performance103.14%103.14%74.39%14.49% Vor Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VORVor Biopharma2.7451 of 5 stars$31.28+12.0%$113.83+263.9%+88.4%$198.13MN/A-18.96140Analyst UpgradeGap DownAVXLAnavex Life Sciences3.8442 of 5 stars$9.09-3.0%$44.00+384.0%+55.0%$804.83MN/A-15.9540IMNMImmunome2.1647 of 5 stars$9.48+2.9%$22.89+141.4%-24.6%$801.68M$9.04M-3.0840News CoverageAnalyst ForecastAVBPArriVent BioPharma1.7424 of 5 stars$18.95-3.9%$39.14+106.6%-19.3%$799.61MN/A0.0040PRAXPraxis Precision Medicines2.4264 of 5 stars$40.45+7.3%$85.88+112.3%-14.1%$793.67M$8.55M-3.29110GOSSGossamer Bio3.9446 of 5 stars$3.18-8.1%$8.50+167.3%+208.0%$786.74M$114.70M-5.13180Analyst DowngradeAKBAAkebia Therapeutics3.8232 of 5 stars$2.92-1.0%$6.75+131.2%+116.0%$782.18M$160.18M-17.18430Positive NewsVALNValneva2.649 of 5 stars$8.93-0.1%$15.00+68.0%+69.7%$768.19M$183.52M-9.11700NAGENiagen Bioscience1.594 of 5 stars$9.68+0.7%$13.42+38.6%N/A$766.43M$99.60M73.92120SANASana Biotechnology3.1362 of 5 stars$3.23+0.3%$8.00+147.7%-20.3%$765.74MN/A-3.05380Positive NewsAnalyst ForecastOCSOculis2.9154 of 5 stars$17.33-0.4%$35.75+106.3%+48.5%$759.73M$780K0.002Analyst Downgrade Related Companies and Tools Related Companies AVXL Competitors IMNM Competitors AVBP Competitors PRAX Competitors GOSS Competitors AKBA Competitors VALN Competitors NAGE Competitors SANA Competitors OCS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:VOR) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vor Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VOR Stock Alerts